Vimarsana
Biggest News Aggregation in the World

Page 2 - Daniel Curran News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Daniel Curran. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Daniel Curran Today - Breaking & Trending Today

Woman abandoned by her dad discovers she's inherited all his land and property in Italy - Vimarsana News

Woman abandoned by her dad discovers she's inherited all his land and property in Italy

Amy Fabris, 49, a dental nurse from Bournemouth, had no idea her father, Giampietro, was living in the UK until after he died in 2020 - and she was shocked to discover she was due his estate

Newcastle RNLI and Lifeguards Assist in Rescue of Ill Walker - Vimarsana News

Newcastle RNLI and Lifeguards Assist in Rescue of Ill Walker

The weather and sea conditions were fine, allowing for a short passage to the scene

Source: afloat.ie
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura cTTP - Vimarsana News

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura cTTP

Takeda TSE 4502NYSETAK today presented favorable interim results from a global pivotal Phase 3 randomized controlled openlabel crossover trial evaluating the safety and efficacy of TAK755 recombinant ADAMTS13 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura cTTP and pharmacokinetics PK characteristics of TAK755 as well as longterm data on TAK755 prophylaxis from a Phase 3b continuation study.

TAK-755 trumps plasma-based therapy, trial shows - Vimarsana News

TAK-755 trumps plasma-based therapy, trial shows

Compared to plasma-based therapies, TAK-755 (recombinant ADAMTS13) protein showed strong efficacy in a trial for cTTP, Takeda revealed.

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP) - Vimarsana News

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2023--